Previous Close | 66.20 |
Open | 66.10 |
Bid | 65.85 x 1500 |
Ask | 66.05 x 8800 |
Day's Range | 65.70 - 66.30 |
52 Week Range | 14.52 - 68.00 |
Volume | |
Avg. Volume | 423,030 |
Market Cap | 2.482B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.53 |
Earnings Date | Apr 29, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 56.00 |
PLANEGG/MUNICH, Germany, April 29, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety ...
Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.